Green Tea Catechin Extract Supplementation Does Not Influence Circulating Sex Hormones and Insulin-Like Growth Factor Axis Proteins in a Randomized Controlled Trial of Postmenopausal Women at High Risk of Breast Cancer.
breast cancer
catechins
green tea extract
insulin-like growth factors
postmenopausal women
sex hormones
Journal
The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
04
09
2018
revised:
15
11
2018
accepted:
14
12
2018
pubmed:
31
3
2019
medline:
2
4
2020
entrez:
31
3
2019
Statut:
ppublish
Résumé
Consumption of green tea has been associated with reduced risk of breast cancer. Hormonal modulation has been suggested as one of the potential underlying mechanisms; however, it has yet to be fully elucidated in large, long-term human clinical trials. We investigated the effects of decaffeinated green tea extract (GTE) on circulating sex hormones and insulin-like growth factor (IGF) proteins. We conducted a placebo-controlled double-blind randomized clinical trial recruiting from 8 clinical centers in Minnesota. Participants were 538 healthy postmenopausal women randomly assigned to the GTE group (463 completed the study; mean age = 60.0 y) and 537 to the placebo group (474 completed; mean age = 59.7 y). Women in the GTE group orally took 4 decaffeinated capsules containing 1315 mg total catechins including 843 mg epigallocatechin-3-gallate daily for 1 y, whereas women in the placebo group took similar capsules containing no tea catechins. Blood sex hormones (estrone, estradiol, androstenedione, testosterone, and sex hormone-binding globulin) and IGF proteins (IGF-1 and IGF binding protein-3) were quantified at baseline and months 6 (for IGF proteins only) and 12, and were assessed as secondary outcomes of the study using a mixed-effect repeated-measures ANOVA model. Women in the GTE group had significantly higher blood total estradiol (16%; P = 0.02) and bioavailable estradiol (21%; P = 0.03) than in the placebo group at month 12. There was a statistically significant interaction between GTE supplementation and duration of treatment on estradiol and bioavailable estradiol (both Ps for interaction = 0.001). The catechol-O-methyltransferase genotype did not influence blood sex hormones before or after GTE supplementation. The circulating concentrations of IGF proteins were comparable between GTE and placebo groups at all 3 time points. These results suggest that a 12-mo GTE supplementation significantly increases circulating estradiol concentrations in healthy postmenopausal women. This trial was registered at clinicaltrials.gov as NCT00917735.
Sections du résumé
BACKGROUND
Consumption of green tea has been associated with reduced risk of breast cancer. Hormonal modulation has been suggested as one of the potential underlying mechanisms; however, it has yet to be fully elucidated in large, long-term human clinical trials.
OBJECTIVE
We investigated the effects of decaffeinated green tea extract (GTE) on circulating sex hormones and insulin-like growth factor (IGF) proteins.
METHODS
We conducted a placebo-controlled double-blind randomized clinical trial recruiting from 8 clinical centers in Minnesota. Participants were 538 healthy postmenopausal women randomly assigned to the GTE group (463 completed the study; mean age = 60.0 y) and 537 to the placebo group (474 completed; mean age = 59.7 y). Women in the GTE group orally took 4 decaffeinated capsules containing 1315 mg total catechins including 843 mg epigallocatechin-3-gallate daily for 1 y, whereas women in the placebo group took similar capsules containing no tea catechins. Blood sex hormones (estrone, estradiol, androstenedione, testosterone, and sex hormone-binding globulin) and IGF proteins (IGF-1 and IGF binding protein-3) were quantified at baseline and months 6 (for IGF proteins only) and 12, and were assessed as secondary outcomes of the study using a mixed-effect repeated-measures ANOVA model.
RESULTS
Women in the GTE group had significantly higher blood total estradiol (16%; P = 0.02) and bioavailable estradiol (21%; P = 0.03) than in the placebo group at month 12. There was a statistically significant interaction between GTE supplementation and duration of treatment on estradiol and bioavailable estradiol (both Ps for interaction = 0.001). The catechol-O-methyltransferase genotype did not influence blood sex hormones before or after GTE supplementation. The circulating concentrations of IGF proteins were comparable between GTE and placebo groups at all 3 time points.
CONCLUSION
These results suggest that a 12-mo GTE supplementation significantly increases circulating estradiol concentrations in healthy postmenopausal women. This trial was registered at clinicaltrials.gov as NCT00917735.
Identifiants
pubmed: 30926986
pii: S0022-3166(22)16599-5
doi: 10.1093/jn/nxy316
pmc: PMC6461722
doi:
Substances chimiques
Gonadal Steroid Hormones
0
Plant Extracts
0
Tea
0
Insulin-Like Growth Factor I
67763-96-6
Catechin
8R1V1STN48
Banques de données
ClinicalTrials.gov
['NCT00917735']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
619-627Subventions
Organisme : NCI NIH HHS
ID : P30 CA077598
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA127236
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA186873
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000114
Pays : United States
Informations de copyright
Copyright © American Society for Nutrition 2019.
Références
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
pubmed: 10523012
Endocrinology. 2000 Mar;141(3):980-7
pubmed: 10698173
J Clin Endocrinol Metab. 2000 Sep;85(9):3043-8
pubmed: 10999783
J Cell Biochem. 2001;82(3):387-98
pubmed: 11500915
Cancer Causes Control. 2001 Aug;12(6):501-8
pubmed: 11519758
Cancer Res. 2001 Sep 15;61(18):6716-22
pubmed: 11559542
J Natl Cancer Inst. 2002 Apr 17;94(8):606-16
pubmed: 11959894
Food Chem Toxicol. 2002 Jul;40(7):925-33
pubmed: 12065214
J Nutr. 2002 Aug;132(8):2307-11
pubmed: 12163680
Toxicol Sci. 2002 Oct;69(2):354-61
pubmed: 12377984
J Nutr. 2003 Feb;133(2):516-21
pubmed: 12566493
Drug Metab Dispos. 2003 May;31(5):572-9
pubmed: 12695345
Int J Cancer. 2003 Sep 10;106(4):574-9
pubmed: 12845655
Toxicol Sci. 2003 Dec;76(2):262-70
pubmed: 14600287
Cancer Res. 2003 Nov 1;63(21):7526-9
pubmed: 14612555
Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):94-101
pubmed: 14744739
Br J Cancer. 2004 Apr 5;90(7):1361-3
pubmed: 15054454
J Natl Cancer Inst. 2004 Jun 16;96(12):936-45
pubmed: 15199113
Trends Endocrinol Metab. 2004 Jul;15(5):211-4
pubmed: 15223050
Carcinogenesis. 2005 May;26(5):976-80
pubmed: 15661801
Clin Cancer Res. 2005 Mar 1;11(5):1918-27
pubmed: 15756018
J Altern Complement Med. 2005 Dec;11(6):1067-74
pubmed: 16398599
N Engl J Med. 2006 Jan 19;354(3):270-82
pubmed: 16421368
Carcinogenesis. 2006 Dec;27(12):2424-33
pubmed: 16785249
Curr Drug Metab. 2006 Oct;7(7):755-809
pubmed: 17073579
Carcinogenesis. 2007 May;28(5):1074-8
pubmed: 17183063
N Engl J Med. 2007 Apr 19;356(16):1670-4
pubmed: 17442911
Breast Cancer Res Treat. 2008 Feb;107(3):359-69
pubmed: 17484049
Mol Pharm. 2007 Nov-Dec;4(6):819-25
pubmed: 17963356
Cancer Detect Prev. 2007;31(6):499-504
pubmed: 18061364
Carcinogenesis. 2008 Oct;29(10):1967-72
pubmed: 18669903
J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):381-406
pubmed: 19016312
J Nutr. 2009 Feb;139(2):310-6
pubmed: 19074205
J Agric Food Chem. 2006 May 17;54(10):3535-40
pubmed: 19127721
Steroids. 2009 Jun;74(6):512-9
pubmed: 19321131
J Pharm Biomed Anal. 2010 Jan 20;51(2):443-9
pubmed: 19442472
Steroids. 2010 Feb;75(2):169-75
pubmed: 19925815
Ann Epidemiol. 2010 Jan;20(1):74-81
pubmed: 20006278
Lancet Oncol. 2010 Jun;11(6):530-42
pubmed: 20472501
Asian Pac J Cancer Prev. 2009 Dec;10 Suppl:7-22
pubmed: 20553076
Acta Diabetol. 2011 Mar;48(1):1-9
pubmed: 21042815
Int J Mol Epidemiol Genet. 2010;1(2):114-123
pubmed: 21191472
Eur J Nutr. 2012 Feb;51(1):47-55
pubmed: 21445620
Mol Nutr Food Res. 2011 Jun;55(6):921-30
pubmed: 21538855
Br J Nutr. 2011 Dec;106(12):1880-9
pubmed: 21736785
Cancer Prev Res (Phila). 2012 Mar;5(3):393-402
pubmed: 22246619
Mol Nutr Food Res. 2012 Jun;56(6):966-75
pubmed: 22707271
Cancer Prev Res (Phila). 2012 Sep;5(9):1144-54
pubmed: 22827973
Breast Cancer Res. 2010;12(5):R88
pubmed: 22889409
Drug Discov Today Dis Mech. 2012 Jun 1;9(1-2):e41-e46
pubmed: 23734165
Cancer Lett. 2015 Jan 28;356(2 Pt A):231-43
pubmed: 24784887
Food Chem Toxicol. 2015 Sep;83:26-35
pubmed: 26051348
Cancer Causes Control. 2015 Oct;26(10):1405-19
pubmed: 26206423
Am J Clin Nutr. 2015 Nov;102(5):991-4
pubmed: 26354536
Drug Metab Rev. 2017 Feb;49(1):56-83
pubmed: 27826992
Cancer Lett. 1995 Sep 25;96(2):239-43
pubmed: 7585463
Nucleic Acids Res. 1993 Aug 11;21(16):3761-6
pubmed: 8367293
Am J Hum Genet. 1977 Mar;29(2):125-35
pubmed: 848488
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3294-6
pubmed: 8622931
Cancer Lett. 1997 Jan 30;112(2):141-7
pubmed: 9066720
Pharmacogenetics. 1997 Feb;7(1):65-71
pubmed: 9110364
Crit Rev Food Sci Nutr. 1997 Dec;37(8):693-704
pubmed: 9447270
Nutr Cancer. 1998;30(1):21-4
pubmed: 9507508